Systemic treatment in adult uterine sarcomas. by Desar, IME et al.
Systemic treatment in adult uterine sarcomas 
 
I.M.E. Desar1, P.B. Ottevanger1, C. Benson2, W.T.A. van der Graaf1,2,3 
 
1Department of Medical Oncology, Radboud university medical centre, PO Box 9101, 6500 HB 
Nijmegen, The Netherlands. 
2The Royal Marsden NHS Foundation Trust, London, United Kingdom 
3The Institute of Cancer Research, Sutton, London, United Kingdom. 
 
Table of contents 
1. Background 
2. Adjuvant treatment 
2.1. Adjuvant hormonal therapy 
2.1.1. ESS 
2.1.2. uLMS 
2.1.3. HGUS and adenosarcoma 
2.2. Adjuvant chemotherapy in US 
2.3. Adjuvant radiotherapy alone 
2.4. Combined radiotherapy and chemotherapy 
2.5. Conclusion – adjuvant setting 
3. Metastatic treatment  
3.1. Hormonal therapy 
3.1.1. ESS 
3.1.2. uLMS 
3.1.3. Conclusion hormonal therapy – metastatic setting 
3.2. Chemotherapy in US 
3.2.1. Efficacy of chemotherapy in first line 
3.2.2. Efficacy of chemotherapy after failure of the first line 
3.2.3. Conclusion chemotherapy - metastatic setting 
3.3. Other, non cytotoxic, systemic therapy in second line and further 
3.3.1. Immunotherapy 
3.3.2. Targeted therapy 
3.3.2.1. Tyrosine kinase inhibitors directed VEGFR and PDGFR 
3.3.2.2. VEGF-trap/antibody 
3.3.2.3. PDGFR antibody 
3.3.2.4. Other targets 
3.3.2.5. Epigenetic modulators 
4. Conclusion and future directions 
  
Abstract 
Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into 
uterine leiomyosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade 
endometrial stromal sarcoma (HG-ESS), adenosarcomas and high grade undifferentiated sarcoma 
(HGUS). US are often high-grade tumours with a high local recurrence rate and metastatic risk. We 
here discuss the current standard of care and knowledge of systemic therapy for adult uterine 
sarcomas, in particular uLMS, LG-ESS, HG-ESS and HGUS, in both the adjuvant as well as the 
metastatic setting. 
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1. Background 
Uterine sarcomas are rare. Together, they account for 3-9% of all uterine cancers and the annual 
incidence is 0.36/100.000 woman-years.(1, 2) Uterine sarcomas (US) are classified into mesenchymal 
tumours or mixed epithelial and mesenchymal tumours. Mesenchymal tumours are further classified 
as uterine leiomyosarcoma (uLMS, 63%), endometrial stromal sarcoma (ESS, 21%, usually divided 
into low grade (LG-ESS) and high grade (HG-ESS)), adenosarcomas (AS, 5%), high grade 
undifferentiated sarcoma (HGUS, 5%) and other rare subtypes (e.g. alveolar or embryonal 
rhabdomyosarcoma).(3, 4) Mixed epithelial and mesenchymal tumours include uterine 
adenosarcomas and carcinosarcomas.(5-7) Adenosarcomas are mixed tumours with a combination of 
a benign epithelial component and malignant mesenchymal cells. The risk of relapse is markedly 
increased in case of sarcomatous overgrowth.(7) Carcinosarcomas, also called malignant mixed 
Müllerian tumours, are generally regarded of epithelial origin, and therefore are not part of this 
review. The pathology of uterine sarcomas is known to be difficult. In a population-based study of 
uterine sarcomas from Norway 168 out of 419 (29%) initially classified US were on review excluded 
or reclassified as for example leiomyomas or leiomyoma variants according to the WHO criteria.(4) 
Furthermore, the nomenclature has been changed several times. 
The clinical behaviour of the histological subtypes is different. Uterine leiomyosarcomas usually 
present as a bulky tumour in women > 40 years with complaints of vaginal bleeding (56%), a palpable 
pelvic mass (54%) and/or pelvic pain (22%).(8) In a significant part of the patients, the diagnosis is set 
postoperative, instead of the expected leiomyoma(s). Distinction between leiomyoma and 
leiomyosarcoma is made with conventional morphological criteria (mitosis, atypia and necrosis). The 
term STUMP (smooth tumours of undefined malignant potential) is used in a setting when both 
leiomyoma as well as leiomyosarcoma cannot be diagnosed with certainty. Uterine leiomyosarcoma 
are usually high grade with typically a mitotic rate > 15/10 HPF. The prognosis of leiomyosarcoma is 
poor, even when confined to the uterus at the time of diagnosis. Recurrence rates are high; between 
53-71 %, and the overall five-year survival rate is poor.(8)  In a recent Surveillance Epidemiology and 
End Results (SEER) database reporting of 13,089 US cases between 2000-2012, the five-year relative 
survival for the group of uLMS patients was 42%.(5) An earlier SEER paper reports a 5-year disease 
specific survival per stage; stage I–76%, stage II–60%, stage III–45%, and stage IV–29%.(9) In a 
Norwegian study, the five-year survival rate for uLMS was 51% for FIGO stage I and 25% for FIGO 
stage II, whereas all patients with stage III-IV died within 5 years.(4)  
The term endometrial stromal tumor applies to neoplasms typically composed of cells that resemble 
endometrial stromal cells of the proliferative endometrium. ESS are predominantly intramural 
neoplasms exhibiting myometrial invasion and permeation of myometrial lymphovascular spaces. LG-
ESS occurs in women between 40-55 years old of whom > 50% is premenopausal. Patients can 
present with vaginal bleeding, dysmenorrhoea or pelvic pain, but as many as 25% is 
asymptomatic.(8) Typically, hormone receptors (estrogen, progesterone) are positive on the tumour 
cells.(8) LG-ESS frequently have JAZF1 rearrangements.(10) Prognosis of LG-ESS is favourable. 
Recurrences occur in up to one third of the patients and may occur after many years. Five-year 
survival for stage I-II is 90%, compared to 50% for stage III-IV.(11) High grade ESS present with 
abdominal bleeding, an enlarged uterus or pelvic mass at a mean age of 50 years (range 28-67). The 
tumour may appear as intracavitary polypoid or mural masses. The mitotic rate is > 10/ 10 HPF and 
estrogen and progesterone receptors are negative.(8) Recently, a t(10;17)(q22;p13) translocation has 
been identified in a large proportion of high-grade ESS. This rearrangement results in an in-frame 
fusion between YWHAE (exons 1 to 5) and 1 of the 2 highly homologous genes FAM22A and FAM22B 
(exons 2 to 7), formerly designated as YWHAE-FAM22 and nowadays called YWHAE-NUTM2.(12-14) 
The presence YWHAE-NUTM2 helps to discriminate HG-ESS from the more common low-grade ESS 
with JAZF1 rearrangement and from HGUS with no identifiable molecular aberrations, which is 
important in guiding clinical management.(12, 15) Cyclin D1 can be used as an immunohistochemical 
diagnostic indicator for HG-ESS with YWHAE-NUTM2 rearrangement.(11) Compared to LG-ESS, 
patients with HG-ESS more frequently encounter recurrences and they occur earlier after primary 
diagnosis. In the SEER database, five-year relative survival for all stage low grade and high grade ESS 
together was 72.7 %.(5)  
 
Adenosarcomas are characterized by benign epithelial elements and a malignant mesenchymal 
component. They most commonly present with vaginal bleeding. Pathologic diagnosis is dependent 
on the identification of the characteristic morphologic features. The most common 
immunohistochemical markers for adenosarcoma are CD10 and WT1, but these are not specific. High 
frequency of TP53 abnormalities has been described in high grade AS.(16) The majority of patients 
present with stage I disease, with a 5-year overall survival of 60 to 80 %. Survival is influenced by the 
presence of myometrial invasion, sarcomatous overgrowth, lymphovascular invasion, necrosis, and 
the presence of heterologous elements including rhabdomyoblastic differentiation. The reported 
prevalence of sarcomatous overgrowth in patients with uterine adenosarcoma varies greatly, from 
8% to 65%.(17) Patients with sarcomatous overgrowth have significantly increased risk of recurrence 
23 versus 77 % and decreased 5-year overall survival 50 to 60 %.(7) Comparable numbers have been 
reported in a National Cancer Database study, with a ten years overall survival of approximately 60% 
in a cohort with 1137 uterine AS patients.(18) 
 
HGUS are very rare and aggressive. They are poorly differentiated sarcomas composed of cells that 
do not resemble proliferative-phase endometrial stroma. HGUS are separated into uniform and 
pleomorphic types. Uniform-type HGUS shows permeative myometrial involvement with 
lymphovascular embolism and no destructive involvement of the myometrium in contrast to 
pleomorphic undifferentiated ESSs. Uniform-type HGUS shows fusiform spindle cells or round cells. 
Pleomorphic-type HGUS exhibits high-grade cytological atypia with marked nuclear pleomorphism 
accompanied in most instances by a high mitotic rate (almost always exceeding 10 MF/10 HPF and 
sometimes approaching 50 MF/10 HPF) and the presence of tumor necrosis. HGUS is often 
heterogeneous and composed of different components, e.g. dedifferentiated ESS, dedifferentiated 
leiomyosarcomas, the sarcomatous component of adenosarcomas or carcinosarcomas with 
overgrowth of epithelial elements, etc.(15) Approximately 60% of the patients present with stage III 
or IV disease. The prognosis is very poor with a median survival, once metastasised of less than a 
year.(8, 19)  
We here review the results of systemic treatment in uLMS and ESS in the adjuvant and metastatic 
settings. The limited available data on AS and HGUS will also be discussed. 
 
 
 
2. Adjuvant treatment 
As described above, the recurrence rates can be high and disease specific survival may be low in 
some types of US, especially uLMS. Important risk factors are high mitotic count, tumour spill and 
morcellation of suspected benign leiomyoma which appear to be leiomyosarcomas by pathology 
review afterwards. Several attempts have been made to improve disease free survival by adding 
adjuvant therapy. 
 2.1 Hormonal therapy 
Both uLMS and ESS can express estrogen receptors (ER) and/or progesterone receptors (PR). For 
uLMS, ER expression has been reported in 18-87% and PR expression in 18-80%. In ESS, ER expression 
has been shown in 40-100% and PR expression 60-100%.(20) HGUS do not express hormone 
receptors. Adenosarcoma may express both estrogen and progesterone receptors in both the 
epithelial as well as sarcomatous component, although hormone receptor expression has not been 
seen in the sarcomatous part of tumours with sarcomatous overgrowth.(21) Conflicting data have 
been published about the association between hormone receptor expression and prognosis.(22-29)  
There are no prospective randomized controlled studies of hormonal therapy in uterine sarcomas, 
neither in the adjuvant nor in the metastatic setting.(30) We here summarize the outcome of series 
of at least ten patients or more. 
 
2.1.1. ESS 
In a retrospective series, four out of thirteen ESS patients who received progestins as adjuvant 
therapy recurred compared with 6 of 9 ESS patients who did not receive adjuvant progestins (31% vs. 
67%).(31) Another retrospective series reports the results of adjuvant hormonal therapy (mainly 
megestrol acetate or medroxyprogesterone) in thirty low grade ESS patients. The median overall 
survival with hormonal therapy was 94 months in the patients with adjuvant hormonal therapy 
versus 72months in the observation cohort (p=0.07).(32) Cheng et al reported a series of 25 low 
grade ESS who had a median time to progression after adjuvant hormonal therapy of 132 
months.(33) In 10 FIGO stage I-II ESS patients treated with adjuvant hormonal therapy (megestrol 
acetate of aromatase inhibitors), no relapse occurred. Patients were treated between 1977-2007 and 
the results were reported in 2010, without mentioning the median follow up time.(34) In a Chinese 
retrospective series, 11 out of 114 low grade ESS received some form of adjuvant hormonal therapy. 
Disease free survival did not differ from patients without or another type of adjuvant treatment and 
no other details are available.(35) Finally, Amant et al reported the results of adjuvant hormonal 
treatment, defined as a minimum of 200 mg medroxyprogesterone acetate, in 2 out of 22 (9%) and 5 
out of 9 (56%) of ESS patients with stages I and III–IV, respectively. Among stage I women receiving 
adjuvant hormonal treatment or not, 0 out of 2 (0%) and 4 out of 20 (20%) relapsed. And among 
stages III–IV women receiving adjuvant hormonal treatment or not, 1 out of 5 (20%) and 3 out of 4 
(75%) relapsed.(36) All together, there is no evidence to support the use of  adjuvant hormonal 
therapy as standard of care in ESS  
 
2.1.2. uLMS 
Even less data is available for uLMS and the use of adjuvant hormonal treatment. The results of 
recently finished randomized phase II study of letrozole versus observation in patients with newly 
diagnosed uLMS limited to the uterus with at least 10% estrogen receptor expression [NCT00414076] 
are awaited.  
 2.1.3. HGUS and adenosarcoma 
There is no literature about adjuvant hormonal therapy in HGUS and adenosarcomas. This makes 
sense since the lack of hormone receptor expression in HGUS. In adenosarcomas, hormone receptor 
expression has been reported, but we did not found any (adjuvant or palliative) trials or series of ten 
or more patients treated with hormonal therapy.(21) However, the other way around, 
adenosarcomas have been associated with tamoxifen use in breast cancer.(37) 
 
2.2 Adjuvant chemotherapy in US 
Only a few prospective studies with adjuvant chemotherapy have been performed and these are 
summarized in table 1.(38-41) The populations of these studies were mixed, including also 
carcinosarcomas, and had small numbers. These prospective results do not support adjuvant 
treatment so far.  However, it is encouraging that in a single arm phase II study of 47 high grade 
uLMS patients treated with 4 cycles of gemcitabine-docetaxel followed by 4 cycles of doxorubicin, 
the median PFS was not yet reached after a median of 39.8 months of follow up.(39)  
To date four retrospective series in US have been reported with at least one chemotherapy 
containing arm. The largest series is an observational cohort study of the National Cancer Database 
in FIGO stage I ESSS. Out of 2414 women with LG- ESS, 4.8% (n=115) received adjuvant 
chemotherapy. Approximately one-third (33.4%, 444/1383) of women with HG-ESS received primary 
adjuvant chemotherapy, and of these women 75.9% (337/444) received multi-agent chemotherapy. 
Use of adjuvant chemotherapy and radiotherapy were associated with increased survival for HG- ESS, 
but not in LG-ESS.(42) A second retrospective study in 108 high grade stage I-II uLMS patients 
comparing adjuvant chemotherapy to radiotherapy or observation did also report no clinical benefit 
of any adjuvant treatment.(43) The same was the case in a very recent retrospective series of 111 
stage I uLMS patients of whom 33 patients received a median of 4 cycles of gemcitabine-docetaxel, 
without survival benefit.(44) The fourth study by Roque et al presented a retrospective series of 56 
uLMS patients treated with chemotherapy (30 gemcitabine-docetaxel, 26 other) compared to 
radiotherapy (n=41) and observation (n=31). There was no difference in PFS or OS in women with 
uLMS treated with adjuvant gemcitabine-docetaxel versus those who were observed or received 
irradiation alone or a chemotherapy regimen other than gemcitabine-docetaxel.(45) 
In July 2016, a systematic review and meta analysis was published. Of 360 early stage uLMS patients 
included, 40% received adjuvant chemotherapy (with or without radiotherapy). These patients were 
compared to radiotherapy alone or observation (53 and 155 patients). Chemotherapy did not prove 
to be of benefit in terms of local or distant recurrence rate.(46)  
Prospective randomized trials are desperately needed in this disease with high relapse risk. 
Unfortunately, the Gynaecologic Oncology Group (GOG) 277 phase III trial comparing 4 cycles of 
gemcitabine-docetaxel followed by 4 cycles of doxorubicin versus observation in high risk uLMS was 
closed prematurely due to poor accrual [NCT01533207]. One of the important reasons of the 
difficulty in running this study was the difference between the intensive treatment arm with 8 cycles 
of chemotherapy and an observation only arm. Also, for patients just recovering from surgical 
procedures the prospect of 8 cycles of chemotherapy could be felt quite challenging. 
The lack of a universally recognised standard chemotherapy comparator arm, continues to hamper 
the development of future randomised clinical trials in this setting. Currently the general perception 
is that there is no routine role for adjuvant therapy, although in practice it may be offered in cases 
where tumour morcellation took place and other indications with obvious tumour spill during 
surgical removal of the tumour. 
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Table 1. Adjuvant chemotherapy trials in uterine sarcomas. 
M; median, DFS; disease free survival, PFS; progression free survival, OS; overall survival, US; uterine 
sarcomas. *including carcinosarcomas 
 
2.3 Adjuvant radiotherapy alone 
Only one prospective trial in early stage (I-II) US is available. Adjuvant radiotherapy was compared to 
observation and did not result in an improvement of local control, the rate of  distant metastases, or 
OS.(47) Furthermore, a recent report of the SEER database even concluded that (retrospectively) 
survival was worse in patient treated with surgery and adjuvant radiotherapy compared to surgery 
alone.(5) Therefore, there is no routine role for radiotherapy in this setting. 
 
2.4 Combined radiotherapy and chemotherapy 
In the SARCGYN trial, 81 patients with FIGO stage ≤ III US (11% HGUS,  including carcinosarcomas) 
were treated with four cycles of doxorubicin 50 mg/m2 d1, ifosfamide 3 g/m2, d1-2, cisplatin 
75mg/m2 d3, (API) and G-CSF q 21 days followed by radiotherapy compared to radiotherapy alone. 
This study was closed prematurely because of poor accrual. The 3-year disease free survival rates 
were 55 vs. 41% (p=0.048), respectively, but without improvement of the 3-year OS (81vs 69%, 
p=0.41), respectively. Toxicity was high with grade 3-4 toxicity (mainly bone marrow suppression) in 
up to 76% of patients and two toxic deaths due to febrile neutropenia. 
 
2.5 Conclusion - adjuvant setting 
Currently, there is neither prospective, nor retrospective, evidence in favour of adjuvant treatment 
for uterine sarcomas. However, expert opinions mention the possibility to consider adjuvant therapy 
in selected cases with high risk US. On individual base, for hormone receptor positive HG-ESS 
hormonal therapy might be considered, carefully balancing the unproven efficacy versus the possible 
negative effects. Because of its good prognosis, adjuvant hormonal therapy in LG-ESS is not clinically 
meaningful. For uLMS, adjuvant chemotherapy (e.g. 4-6 cycles of doxorubicin or gemcitabine-
docetaxel) might be considered in younger and otherwise healthy patients with a high risk on 
recurrence (e.g. high grade, tumour spillage or morcellation), after discussion in a multidisciplinary 
sarcoma tumour board. For HGUS, unfortunately, no conclusion can be made with the unfortunate 
premature closure of the phase III study. 
 
 
 
 
3. Metastatic treatment 
3.1 Hormonal therapy 
3.1.1. ESS 
Again, only case reports and small retrospective series are available. We here discuss series of at 
least 10 patients. The Royal Marsden Hospital single experience observed objective response in 
46.2% and clinical benefit in 92.4% in 13 metastatic ESS patients treated with first line hormonal 
therapy. Aromatase inhibitors were prescribed as first endocrine line in 11 out 13 patients and 
progestins in the remainder, while in second line treatment other aromatase inhibitors were 
prescribed in 7 out of 10 patients, followed by progestins and GnRH analogues. Median PFS for first 
line was 4.0 years, with a 5-year PFS rate of 30.8%. Median PFS for second line hormonal treatment 
was 3.0 years, with a 2-year PFS rate of 88.9% (95% CI: 68.3 - 100.0).(48) A Dutch series of 11 LG-ESS 
patients with residual or recurrent disease treated with megestrol acetate or aromatase inhibitors, 
observed in 9 (82%) patients an objective response (4 complete responses; 5 partial responses). The 
response duration ranged from 4 to 252 months (median 48 months).(49) Ioffe et al. reported stable 
disease, complete or partial response in 14 of 18 ESS patients with recurrent or progressive disease 
who were treated with hormonal therapy (range of follow up: 6–124 months).(29) 
In second line, only case reports are available.(50, 51).  
Importantly, all case series are small and retrospective, and the natural behaviour of ESS can be 
indolent. 
 
3.1.2. uLMS 
Only one prospective phase II trial with letrozole has been performed in 27 ER and/or PR positive 
uLMS patients with a median of 2 prior lines of systemic therapy. The median PFS was 12 weeks. The 
best response was stable disease in 14 patients (54%). Three patients,  all with tumours expressing 
ER and PR in > 90% of tumour cells, continued to receive letrozole for > 24 weeks. Median duration of 
therapy for the study population was 10 weeks. The most common reason for treatment 
discontinuation was disease progression (85%). (52) In a retrospective series with sixteen patients 
with measurable advanced uLMS, patients were treated with an aromatase inhibitor (first line mainly 
letrozole, second line mainly exemestane). Median PFS in first line was 14 months, and prolonged 
PFS was more likely to be observed in patients with low grade compared to high grade ULMS (20 
months vs. 11 months), and in moderate strong ER positive compared to weak ER positive ULMS 
(20 months vs. 12 months). Best response was a partial response in 2 out of 16 patients (12.5%) and 
the clinical benefit rate, defined as complete response plus partial response plus stable disease 
≥6 months, was observed in 10 out of 16 patients (62.5%). Median duration of second line was 
3 months and median PFS was not reached. The 1-year PFS rate for the second line aromatase 
inhibitor was 80%.(53) The Memorial Sloan-Kettering Cancer Centre presented their experience in 34 
advanced or recurrent uLMS patients (65% ER+, 29% PR+) treated with aromatase inhibitors. Median 
PFS was 2.9 months and best objective response was partial response in 3 out of 34 patients (9%) (all 
of whom were ER positive). In the subgroup with ER or PR positive uLMS, the 1 year progression free 
survival rate was 28%.(54)  
 
3.1.3. Conclusion hormonal therapy- metastatic setting 
Although prospective evidence is scarce, the series presented do show that in selected cases (e.g. ER 
and/or PR positive, low grade, low volume disease) hormonal therapy can be attractive in stabilising 
disease and ultimately postponing chemotherapy. This is more the case in ESS than in uLMS. In the 
majority of patients, hormonal therapy has the advantage of being well tolerated and less toxic than 
systemic chemotherapy. However, almost all presented data are retrospective.  A selection and 
publication bias must be considered and there is a lack of systematic analysis of the hormone 
receptor status. The lack of available data of control patients makes it difficult to interpret the results 
of the observations as discussed. Objective radiological response is the most convincing indication of 
efficacy of treatment in these uncontrolled studies and case series. 
 
3.2. Chemotherapy in US 
Despite many efforts, the 5-years disease specific survival for all types of locally advanced and 
metastatic US (including carcinosarcomas) did not improve in the past decennium.(5, 9) Multiple 
prospective trials with palliative chemotherapy have been done (Table 2). They encompass the whole 
range, from smaller studies in uLMS only to larger soft tissue sarcoma (STS) trials including also 
uterine sarcoma or leiomyosarcoma patients of non-uterine origin.  Due to its rarity and its more 
indolent behaviour, only small numbers of ESS and HGUS patients have been included in STS trials. 
Furthermore, one must consider that part of the prospective trials and all of the retrospective series 
have been done without  central pathology review  and that up to 30% of the pathological diagnosis 
may be wrong.(4) 
The National Cancer Database of the United States concluded that chemotherapy adds 8.5 months 
benefit compared to untreated patients with metastatic uLMS (19.4 vs. 10.9 months) in an 
observational cohort study of patients diagnosed between 1998-2013.(42) Recently, a pooled 
analysis of 269 metastasised US patients treated within 13 trials (total 3270 STS patients) of the 
EORTC Soft Tissue and bone Sarcoma has been published.(55) Median OS was 10.4 months, median 
PFS 4.1 months. Four categories of chemotherapy were evaluated; anthracyclines alone, ifosfamide 
alone, combined doxorubicin-ifosfamide and the combination of cyclophosphamide, doxorubicin, 
vincristine and dacarbazine (CYVADIC). Clinical outcome was not influenced by category of 
chemotherapy. Histological subtypes were grouped as LMS versus others. Lower response rates were 
observed in LMS (19 versus other 33%) and the response for ifosfamide as single agent was only 5% 
for al US. Gemcitabine-docetaxel was not part of this analysis. 
In table 2 we summarize the prospective trials with palliative chemotherapy in US or STS trials 
important for the nowadays insights in the standard of care for STS in general including US. Where 
available, numbers of (u)LMS within general STS trials have been provided.  The majority of the  
studies had negative results and did not improve the survival of patients with advanced or metastatic 
uterine sarcomas. We here discuss the prospective trials summarized in table 2.  
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topotecan(71) uLMS 1 II 36 11 Median duration of response 
3.3 months. 
2000 
dacarbazine-
mitomycin-
doxorubicin-
cisplatin-
sargramostim(
72) 
uLMS 1 II 18 27.8 - - 5.9 14.2 2005 
mitomycin-
doxorubicin-
cisplatin(73) 
uLMS 1 II 37 23 - - - 6.3 2002 
etoposide(74) uLMS 1 II 28 0 - - 2.1 9.2+ 1996 
First or second line 
gemcitabine-
docetaxel(75) 
LMS 1 or 
2 
II 34(85
%) 
52.9 64.7 47 5.6 17.9 2002 
High dose 
ifosfamide 12 
gr/m2 in 3 
days every 28 
days(76) 
STS 1 or 
2  
II 124 
(33) 
16% 
(LMS 
5%) 
- - 15 
we
eks 
- 2000 
Paclitaxel-
carboplatin(77
) 
US 1 or 
2 
II 13 15.4 - - 2.2 12.4 2012 
trimetrexate(7
8) 
uLMS 1 or 
2 
II 23 4.3 - - 2.2 7.2+ 2002 
Second line 
gemcitabine-
docetaxel (79) 
ulMS 2 II 51 27 73 52 5.6
+ 
- 2008 
gemcitabine-
docetaxel(80) 
uLMS 
cohort 
2 II 21 23.8 71.4 47.6 4.7 23 2008 
gemcitabine(8
1) 
uLMS 2 II 42 20.5 - - 4.9 - 2004 
ixabepilone(8
2) 
uLMS 2 II 26 0 - - 1.4 7.0 2014 
etoposide(83) uLMS 2 II 29 6.9 - - 2.1 7.6+ 1998 
Beyond second line 
gemcitabine-
darcabazine 
vs. 
dacarbazine(8
4) 
STS ≥2 II 109 
(32 
LMS) 
12 
vs. 4 
56 
vs. 
37 
- 4.2 
vs. 
2 
(LM
S 
4.9) 
16.8 vs 
8.2 (LMS 
18.3) 
2011 
trabectedin vs 
dacarbazine(8
5) 
LMS or 
lipo 
≥3 III 518 
(40% 
uLMS) 
9.9 
vs 
6.9 
- - 4.2 
vs. 
1.5  
12.4 vs. 
12.9, HR 
0.58 in 
uLMS 
subgroup 
2016 
eribulin vs 
dacarbazine(8
6) 
LMS or 
lipo 
≥3 III 452 
(297 
LMS of 
who 
131 
uLMS) 
4-5 33 vs 
29 
- 2.6 
vs 
2.6 
13.5 vs. 
11.5 
(benefit 
mostly for  
lipo) 
2016 
All lines 
Gemcitabine-
docetaxel(87) 
STS All IV 228(57
LMS) 
16% 
(LMS 
26.3
%) 
  3.3 10.3 2017 
gemcitabine-
docetaxel(88) 
uLMS All - 9 33 - - - - 2014 
doxorubicin 
vs. 
doxorubicin+ 
dacarbazine(8
9) 
US All III 226 
(72 
uLMS, 
15 
ESS, 
17 
HGUS) 
16 
vs. 
24 
- - 3.5 
vs. 
5.5 
7.7 vs. 7.3 1983 
mitoxantrone(
90) 
US All II 29  
12 
uLMS 
17 
MMT 
0  
 
- - 1.4 4.1 1990 
Table 2. Chemotherapy trials in advanced or metastastic uterine sarcomas. 
M; median, mo; months, RR; response rate, PFS; progression free survival, OS; overall survival, US; 
uterine sarcomas, uLMS; uterine leimyosarcoma, LMS; leiomyosarcoma, lipo; liposarcoma, ESS 
endometrial stromal sarcoma, HGUS; high grade uterine sarcoma, MMT; mixed Müllerian tumour, 
STS; soft tissue sarcoma 
 
 
3.2.1. Efficacy of chemotherapy in first line  
As in other soft tissue sarcomas, doxorubicin is still the first line treatment in uterine sarcomas. 
Mainly all first line trials in US or (u)LMS were doxorubin based or used gemcitabine-docetaxel.(56, 
58, 72, 73, 75, 79, 80) For a long time, it was debated whether single agent doxorubicin or the 
combination of gemcitabine-docetaxel was best in (u)LMS. Recently, the results of the UK GeDDiS 
Phase III trial have been published. This trial included 257 patients with STS who were randomized 
between doxorubicin 75 mg/m2 q 21 days or the combination of gemcitabine 650 mg/m2 Day 1 and 
8, q21 days and docetaxel 75 mg/m2 every 21 days. No significant difference in median PFS (23.3 and 
23.7 weeks) or median OS (76.3 vs. 76.3 weeks) for doxorubicin versus gemcitabine-docetaxel were 
reported and response rates of 20 and 19% for both treatment arms. Further subgroup analyses 
were done comparing leiomyosarcoma versus other sarcomas (p=0.14), and uterine leiomyosarcoma 
versus other sarcomas (p=0.38), but again no differential effect was evident between the two 
treatment groups.(57) The authors concluded that single agent doxorubicin is still the preferred first 
line treatment in STS and the results in the (u)LMS cohort do not support other preferences. The 
addition of olaratumab to doxorubicin showed an impressive improvement of OS compared to 
doxorubicin alone in the Phase Ib-II trial (26.5 vs. 14.7 months) in unselected STS but needs 
confirmation in a Phase III trial, which has recently completed accrual and results are expected 
around 2019-2020.(66) [NCT02451943] In those STS patients in need for a volume response (e.g. 
induction therapy or because of palliative reasons) the combination of doxorubicin and ifosfamide is 
recommended.(62) However, the European Society of Medical Oncology (ESMO) guidelines suggests 
the combination of doxorubicin-dacarbazine (67, 89) instead of doxorubicin combined with 
ifosfamide in case combination therapy is warranted, since the activity of ifosfamide is limited in 
uterine leiomyosarcomas.(55, 67, 91) Anthracycline based combination therapy in first line palliative 
treatment is considered to be more toxic and should be reserved for patients in need for a volume 
response, e.g. in case of severe symptoms.  
Based on an encouraging objective response rate of 60% in the uLMS subgroup treated with the 
combination of doxorubicin and trabectedin in a non-randomised phase II trial(68), a phase III trial; 
combining doxorubicin plus trabectedin versus doxorubicin followed by trabectedin in uterine or soft 
tissue leiomyosarcoma patients is currently in preparation. [NCT02997358] Recently, a randomised 
phase II study of Martin-Broto et al. with the same combination in STS patients versus doxorubicin 
was closed because of futility after interim analysis.(92) 
 
3.2.2. Efficacy of chemotherapy after failure of the first line 
Multiple trials have been performed in second line and further. The results are summarized in table 
2. Proportions of (u)LMS patients in US or STS trials have been mentioned but should be interpreted 
with caution since these trials were not powered for subgroup analyses. The results do not warrant a 
different approach for uterine sarcomas as for STS in general, although details may be slightly 
different. Again, ifosfamide is less frequently used in (u)LMS both in first as well as in second line.(55) 
Trabectedin (68, 85) and dacarbazine(84, 86) are the most frequently  used drugs. A direct 
comparison has been made in a phase III trial with trabectedin vs. dacarbazine in patients with 
leiomyosarcomas and liposarcomas in third line and further.(85) A total of 518 patients were enrolled 
and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). Median PFS for 
trabectedin vs. dacarbazine was 4.2 vs. 1.5 months; hazard ratio, 0.55; P < 0.001). In the pre-defined 
sub-analyses all subgroups benefited from trabectedin, although the benefit was not statistically 
significant in all these subgroups. The interim analysis of OS (64% censored) demonstrated a non-
significant 13% reduction in risk of death in the trabectedin arm compared with dacarbazine (median 
OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P = 0.37). In a post hoc 
subset analysis of the uLMS cohort of this trial, trabectedin treatment resulted in significantly longer 
PFS versus dacarbazine (4.0 vs. 1.5 months), without difference in OS (14.4 vs. 12.9 months). 
Objective response rate was 11% with trabectedin vs. 9% with dacarbazine (P=0.82) and clinical 
benefit rate for trabectedin was 31% vs. 18% with dacarbazine (P=0.05).(93) 
Despite the negative results for leiomyosarcoma in the recently published phase IIII eribulin trial,  the 
results of the comparator dacarbazine arm are interesting.(86) A total of 452 patients with 
intermediate-grade or high-grade advanced liposarcoma or leiomyosarcoma (28-30% uLMS) who had 
received at least two previous systemic regimens for advanced disease (including an anthracycline) 
were 1:1 randomized to eribulin mesilate or dacarbazine (850 to 1200 mg/m2 intravenously on Day 
1) every 21 days until disease progression. OS was significantly improved in patients assigned to 
eribulin compared with those assigned to dacarbazine (median OS 13.5 vs. 11.5 months; hazard ratio 
0.77). This OS benefit was only seen in liposarcoma patients (median OS 15.6 months vs. 8.4 months, 
respectively) and not in those with leiomyosarcoma (12.7 vs. 13.0 months). Median PFS was similar in 
both treatment groups: 2.6 months. Remarkably, this trial confirms the activity of dacarbazine in 
leiomyosarcoma by its relatively long survival of LMS patients who were included in a third line or 
higher trial. Temozolomide, the prodrug of dacarbazine, had been reported to induce some (partly 
prolonged) responses in a retrospective series of in total 19 patients.(94) 
Due to its rarity, the data on chemotherapy in metastatic ESS are sparse. For both ESS and HGUS, no 
specific conclusions can be withdrawn because of a lack of evidence.   
 
 
3.2.3. Conclusion chemotherapy– metastatic setting 
Most trials focused on STS or (u)LMS, and rarely include patients with ESS or HGUS. By evidence and 
efficacy, first line treatment of choice still remains doxorubicin (+/- olaratumab if available) or 
perhaps doxorubicin-dacarbazine in case of the need of combination therapy. Within the next few 
years, the results of the ongoing phase III trials may (or may not) change this into doxorubin-
olaratumab or maybe doxorubicin-trabectedin. After first line therapy, many drugs have some 
activity but in general the prognosis remains poor. Choice of treatment in this setting includes 
consideration of toxicity profile and patient preference. Trabectedin, dacarbazine and gemcitabine 
based chemotherapy are active options. Clinical trial options should always be considered.  
 
 
3.3. Other, non cytotoxic, systemic therapy in second line and further 
 
Many cancer patients benefit from the big breakthroughs of the past few years, such as 
immunotherapy and targeted therapy. Unfortunately, this is not the case for uterine sarcomas.  
 
 
3.3.1. Immunotherapy 
Only a limited number of studies have been performed to assess efficacy in uterine sarcomas (Table 
3). Uterine LMS exhibit moderate immunohistochemical expression of PD1 (46.9%) and PDL1 
(36%).(95) Only one phase II trial and only one case report on immunotherapy in uterine sarcomas 
have been published so far.(96, 97) In twelve uLMS patients treated with PD-1 inhibitor nivolumab 3 
mg/kg every two weeks, no objective responses where found and median PFS was only 1.8 months. 
Due to a lack of clinical benefit the second part of the study wasn't opened. Archival samples were 
available for 83% of patients. PD-1 (>3% of cells), PD-L1, and PD-L2 (>5% and >10% of tumour cells, 
respectively) expression were observed in 20%, 20%, and 90% of samples, respectively.(97) Very 
recently, a phase II trial testing nivolumab in all types of uterine cancer, including uLMS, HG-ESS and 
HGUS, started recruitment.(NCT03241745)  
Other ongoing immunotherapy studies are not specifically focused on uterine sarcomas. An active 
phase II study is investigating the role of the anti-PD-1 antibody, pembrolizumab, in patients with 
advanced soft tissue and bone sarcomas.(NCT02301039) Furthermore, a phase I-II trial combining 
pembrolizumab with doxorubicin in advanced or metastatic STS is open (NCT02888665), as is a phase 
II study of Talimogene Laherparepvec (T-VEC) combined with pembrolizumab.(NCT03069378) In the 
neoadjuvant setting, anti-PD-L1 (Durvalumab/MEDI4736) plus anti-CTLA-4 (Tremelimumab) and 
radiation is tested for high risk STS.(NCT03116529). The combination of tyrosine kinase inhibitor 
axitinib and pembrolizumab is currently tested in specific types of STS, including LMS after failure of 
anthracyclines.(NCT02636725) As a first line therapy, the combination of trabectedin, nivolumab and 
anti-CTLA-4 ipilimumab is under investigation in a dose finding phase I-II study for advanced 
STS.(NCT03138161)  
 
 
3.3.2. Targeted therapy 
Targeted therapy refers to systemic therapy directed to specific elements or pathways crucial for 
cancer cells to survive. Only results of a few trials or subgroup analyses in uterine sarcomas are 
available (table 3). Some categories of targeted therapy can be distinguished: 
 
3.3.2.1. Tyrosine kinase inhibitors directed against a.o. vascular endothelial growth factor receptor 
(VEGFR) and platelet derived growth factor receptor (PDGFR): 
A subgroup analysis on 34 patients with uterine sarcomas treated the phase II pazopanib trial or 
PALETTE trial showed a response rate of 11%, median PFS of 3.0 months and OS of 11.1 month, 
which was worse compared to the non uterine STS types (mPFS 4.5 months, mOS 17.5 months).(98) 
A randomized phase II study comparing pazopanib combined with gemcitabine to gemcitabine-
docetaxel in STS is currently ongoing.(NCT01593748) Sunitinib 50 mg OD 4 weeks on - 2 weeks of, 
failed to achieve a sufficient number of objective responses (8.7%) or sustained disease stabilization 
(mPFS 1.5 months and 6 months PFS rate 17.4%) as second- or third-line treatment for uterine 
leiomyosarcoma.(99) Cabozantinib, targeting MET as well as VEGFR,  is currently under investigation 
as maintenance therapy after chemotherapy in metastatic HGUS, adenosarcomas, and HG 
ESS.(NCT01979393) 
  
3.3.2.2. VEGF trap/antibody 
VEGF trap aflibercept 4 mg/kg iv every 2 weeks showed similar disappointing results in patients with 
uLMS or carcinosarcomas of the uterus: no objective responses were observed, median PFS was 1.8 
months and the 6 months PFS was 17%.(100) The addition of VEGF antibody bevacizumab to 
gemcitabine-docetaxel did not improve outcome.(58)  
 
3.3.2.3. PDGFR antibody 
As described above, in a randomized phase II trial, addition of PDGFR antibody olaratumab improved 
OS by more than 10 months.(66) The phase III trial is ongoing.[NCT02451943] Currently, the addition 
of olaratumab to gemcitabine-docetaxel is investigated in a phase Ib-II trial in STS.(NCT02659020) 
 
3.3.2.4. Other targets 
Although the PI3K/mTOR pathway has been recognized as a potential target for uLMS in preclinical 
work, no series or (ongoing) trials have been found for US.(101) The same is the case for VIPR2, a 
gene affected in 96% of 84 uLMS samples which seems to act as a tumor suppressor gene.(102) 
 
3.3.2.5. Epigenetic modulators 
Histone deacetylase inhibitor panobinostat in a phase II trial for STS with 10 LMS and 3 ESS patients 
did not result in any objective responses but 2/10 LMS and 2/3 ESS patients had prolonged stable 
disease for more than six months. Pabinostat was poorly tolerated with the need of dose reduction 
in up to one third of the patients due to thrombocytopenia, anaemia, lymphocytopenia, fatigue and 
QTc prolongation.(103) Aurora A kinase inhibitor alisertib was not effective in 21 uLMS patient as no 
objective responses or prolonged stable disease were seen. Median PFS and OS were 1.7 and 
14.5months, respectively.(104)  
 
In conclusion, currently, with respect to targeted agents, only pazopanib has a place in the treatment 
of US after failure of at least anthracyclines. Based on promising phase II results and awaiting the 
outcome of the phase III study, in some countries olaratumab can be added to doxorubicin in first 
line treatment. 
 
TABLE 3 population n 
(%(u)LMS) 
RR (%) 3mo 
PFR 
(%) 
6mo 
PFR 
(%) 
PFS 
(months) 
OS 
(months) 
nivolumab(97) uLMS 12 0 - - 1.8 - 
pazopanib(98)  US 44 11 - - 3 17.5 
regorafenib vs. 
placebo (105) 
STS, 1 
cohort 
LMS 
56 LMS of 
who 22 
uLMS 
0 57 vs. 
25 
21 vs. 
7 
3.7 vs. 
1.8 
21 vs. 9.1 
sunitinib(99) uLMS 23 8.7 - 17.4 1.5 15.1 
thalidomide(106) uLMS 30 0 - - 1.9 8.3 
aflibercept(100) uLMS 41 0 - 17 1.8 18.1 
alisertib(104) uLMS 21 0  0 1.7 14.5 
Table 3. Systemic non-cytotoxic treatment trials in advanced or metastastic uterine sarcomas. 
M; median, mo; months, RR; response rate, PFS; progression free survival, OS; overall survival, US; 
uterine sarcomas, uLMS; uterine leimyosarcoma, LMS; leiomyosarcoma, STS; soft tissue sarcoma. 
 
4. Future directions and conclusion 
Uterine sarcomas encompass  a rare group of diseases with a dismal prognosis of  aggressive 
subtypes. For the choice of systemic treatments, part of the difficulty is the recognition of the 
specific subtype of uterine sarcoma and an adequate pathology diagnosis, including molecular 
analyses. Very recently, new genetic and immunological differences between uLMS, ESS and HGUS 
were shown. Gene expression and immunohistochemical analyses revealed the presence of high 
numbers of tumor-associated macrophages (TAMs) in HGUS, which makes HGUS patients suitable 
candidates for therapies targeting TAMs. Furthermore, a high genomic instability of HGUS and 
downregulation of several TP53-mediated tumor suppressor genes, such as NDN, CDH11, and NDRG4 
were proven. Moreover, it was demonstrated that HGUS carry somatic mutations in several 
oncogenes and tumor suppressor genes implicated in RAS/PI3K/AKT/mTOR, ERBB3, and Hedgehog 
signaling for which targeted therapies exist.(107) 
After the primary diagnosis and treatment by gynaecologists and their multidisciplinary teams, early 
involvement of sarcoma specialists is necessary. Many centres are  only treating a few patients per 
year. All together, this makes it difficult to improve the diagnostic and treatment trajectory of US 
patients. Centralisation of care and the timely collaboration between gynaecological oncologists and 
sarcoma specialists might help to deliver the best knowledge, experience and trial availability to US 
patients. By now, despite many attempts to improve the outcome by systemic treatments, the 
prognosis, both after primary diagnosis and in case of metastatic disease, remains poor. The 
observation of heterogeneity within uterine sarcoma subtypes warrants a personalized treatment 
approach. Further studies with realistic analysis of patients numbers are needed to improve patient 
outcome. Given the experiences so far, this is a challenge at a global level. 
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